Ultrasonic device for tissue ablation and sheath for use therewith

Information

  • Patent Grant
  • 7503895
  • Patent Number
    7,503,895
  • Date Filed
    Monday, February 24, 2003
    22 years ago
  • Date Issued
    Tuesday, March 17, 2009
    16 years ago
Abstract
A transverse mode ultrasonic probe is provided which creates a cavitation area along its longitudinal length, increasing the working surface of the probe. Accessory sheaths are also provided for use with the probe to enable a user to select from features most suited to an individual medical procedure. The sheaths provide acoustic enhancing and aspiration enhancing properties, and/or can be used as surgical tools or as medical access devices, protecting tissue from physical contact with the probe.
Description
FIELD OF THE INVENTION

The present invention relates generally to a shielded ultrasonic medical probe operating in a transverse mode for ablating and removing undesired tissue. In particular, the invention provides one or more acoustical sheaths for use with the probe, allowing the user to control and focus the energy emitted by the probe in a manner most suited to the desired medical procedure.


BACKGROUND OF THE INVENTION

Ultrasonic energy has been considered for tissue ablation and fragmentation of plaque and thrombosis for removal of intravascular occlusions due to atherosclerotic plaque and intravascular blood clots. Surgical devices utilizing ultrasonic probes for generation and transmission of ultrasonic energy, have been disclosed in the art (U.S. Pat. Nos. 5,112,300; 5,180,363; 4,989,583; 4,931,047; 4,922,902; and 3,805,787). Typically, the energy produced by an ultrasonic probe is in the form of very intense, high frequency sound vibrations, results in fragmentation of tissue (plaque and thrombosis) either as a result of mechanical action thereon or “cavitation” thereof, in which high energy ultrasound frequency applied to liquids generates vapor-filled microbubbles or “cavities” with the concomitant rapid expansion and collapse of the cavities that is accompanied by intense localized hydraulic shock, that causes fragmentation or dissolution of the tissue. Medical applications for ultrasonic probes providing cavitation include surgical procedures for ablation of tissues, for example, treatment of cancer, tissue remodeling, liposuction, and removal of vascular occlusions. Typically, ultrasonic probes described in the art for use in surgical procedures include a mechanism for irrigating an area where the ultrasonic treatment is being performed (e.g., a body cavity or lumen) to wash tissue debris from the area, and may further include an aspiration means to remove irrigation fluid and tissue debris from the site of the procedure. Mechanisms used for irrigation or aspiration described in the art are generally structured such that they increase the overall cross-sectional profile of the probe, by including inner and outer concentric lumens proximal to or within the probe to provide irrigation and aspiration channels. In addition to making the probe more invasive, prior art probes may also maintain a strict orientation of the aspiration and the irrigation mechanism, such that the inner and outer lumens for irrigation and aspiration remain in a fixed position relative to one another, which is generally closely adjacent the area of treatment. Thus, the irrigation lumen would not extend beyond the suction lumen (i.e., there is no movement of the lumens relative to one another) and any aspiration would be limited to picking up fluid and/or tissue remnants within the defined distance between the two lumens.


Ultrasonic probes described in the art for tissue ablation suffer from a number of limitations. Such probes depend on longitudinal vibration of the ultrasonic member comprising the probe i.e. vibration of the probe in the direction of the longitudinal probe axis to effect tissue fragmentation. Probe action in this modality therefore depends primarily on mechanical and thermal action of the probe tip for disrupting tissue, since the cavitational energy emanating from the tip, especially in narrow diameter probes such as those used to remove vascular occlusions, is minimal due to the small surface area of the tip itself. This primary mode of action imposes the following limitations on probe efficiency:


i) tissue ablation is restricted to very small area defined by the surface area of the probe tip, thereby necessitating time consuming surgical procedures to remove relatively large occluded areas with blood vessels in comparison to instruments which excise tissue by mechanical cutting, electrocautery, or cryoexcision methods.


ii) occurrence of late restenosis (typically within three months), and to a lesser extent acute re-occlusion after coronary angioplasty are major clinical problems limiting the long-term efficacy of ultrasonic surgical procedures for treatment of atherosclerosis and coronary angioplasty. While the pathogenosis of restenosis is still unclear, it has been demonstrated from autopsy specimens from patients with restenosis the pathophysiologic process leading to acute occlusion after coronary angioplasty is related either to a thrombotic mechanism or to major plaque dissection and superimposed thrombosis, and that these events leading to chronic restenosis involves vascular injury, platelet deposition and thrombosis and connective tissue synthesis. Such post operative processes are typically result from localized trauma at the surgical site caused by mechanical and thermal action of longitudinally vibrating probes.


Attempts to reduce some of the aforementioned problems associated with longitudinally vibrating probes have been disclosed in the art, wherein the primary action of the probe through longitudinal vibration is supplemented by a limited, supplementary transverse vibration of the probe tip i.e. perpendicular to the longitudinal axis of the probe. It is proposed that such secondary transverse vibrations in these probes will result in increased efficiency for surgical procedures. For example, U.S. Pat. No. 4,961,424 to Kubota, et al. discloses an ultrasonic treatment device that produces both a longitudinal and transverse motion at the tip of the probe. The Kubota, et al. device, however, still relies solely on the tip of the probe to act as a working surface. Thus, while destruction of tissue in proximity to the tip of the probe is more efficient, tissue destruction is still predominantly limited to the area in the immediate vicinity at the tip of the probe. U.S. Pat. No. 4,504,264 to Kelman discloses an ultrasonic treatment device, which improves the speed of ultrasonic tissue removal by oscillating the tip of the probe in addition to relying on longitudinal vibrations. Although tissue destruction at the tip of the device is more efficient, the tissue destroying effect of the probe is still limited to the tip of the probe. Both probes described in Kubota, et al., and Kelman, et al., are further limited in that the energy produced at the tip of the probe is unfocused, the action of the probe tends to push the tissue debris ahead of the probe tip. Likewise, the concentration of energy solely at the probe tip results in heating of the probe tip, which can create tissue necrosis, thereby complicating the surgical procedure and potentially compromising the recovery of the patient. Furthermore, such probes do not eliminate the problems associated with longitudinally vibrating probes.


The aforementioned limitations associated with longitudinally vibrating probes can be overcome entirely by utilizing an ultrasonic probe that vibrates exclusively in the transverse mode. Such probes are capable of generating substantially higher cavitational energy through a plurality of anti-nodes along the entire longitudinal axis of the vibrating probe, thereby eliminating the need for mechanical and thermal action at the probe tip. The advancing probe tip can therefore be shielded to prevent mechanical injury to the walls of the blood vessel for example, thereby precluding scarring, platelet deposition and clotting that lead to restenosis. Additionally, such probes are capable of tissue fragmentation over greater surface area (along the entire longitudinal axis) resulting in high efficiency, thus allowing for rapid surgical procedures and substantially eliminating thermal effects on tissue caused by prolonged probe operation.


Since probe vibrating exclusively in a transverse mode is entirely dependent on cavitational energy for their action, important factors for maintaining efficiency of such probes are (i) narrow probe diameter to facilitate oscillation at lower ultrasonic energies and (ii) increased longitudinal axis (probe length) that results in more cavitation anti-nodes. Although narrow probe diameters are advantages especially for negotiation through narrow blood vessels and occluded arteries, the utilization of such probes have been precluded by inability to effectively control the vibrational amplitude of thin probes, that result in potential damage to the probe and greater risk, of tissue damage resulting from their use. The use of narrow diameter probes have been disclosed in the art for providing greater maneuverability ease of insertion in narrow blood vessels. U.S. Pat. No. 4,920,954 to Allinger discloses a narrow diameter ultrasonic device wherein a rigid sleeve is used to prevent transverse vibrations U.S. Pat. No. 5,380,274 discloses a narrow diameter probe for improved longitudinal vibration having a sheath to inhibit transverse vibration U.S. Pat. No. 5,469,853 to Law discloses a thin, longitudinally vibrating ultrasonic device with a bendable sheath that facilitates directing the probe within narrow blood vessels. While the prior art has focused on the need for using sheaths on thin ultrasonic devices, their use has been entirely to prevent transverse, vibrations of the device and to protect such devices from damage resulting from such vibrations


Based on the aforementioned limitations of ultrasonic probes in the art, there is a need for ultrasonic probe functioning in a transverse mode that further obviates the shortcomings of that further overcomes limitations imposed by of narrow diameter requirements for efficient operation of such probes for rapid tissue ablation. Transversely vibrating ultrasonic probes for tissue ablation are described in the Applicant's co-pending provisional applications U.S. Ser. Nos. 60/178,901 and 60/225,060, and 09/776,015 which further describe the design parameters for such a probe its use in ultrasonic devices for tissue ablation. The entirety of these applications are herein incorporated by reference.


There is a further need for controlling the for procedures which require precise delivery of cavitation energy to defined locations, to be able to restrict the cavitation energy emanating circumferentially from a transversely vibrating p at multiple anti-nodes wastes a portion of the energy given off by the probe, as the energy is unfocused and dispensed along the length of the probe.


There is also a need in the art for a means of focussing the cavitational energy emitted by such a probe to deliver the energy to exactly to the desired location within a blood vessel while shielding the surrounding tissue from damage.


SUMMARY OF THE INVENTION

The present invention is directed towards a transversely vibrating ultrasonic probe for tissue ablating surgical devices that overcomes the aforementioned limitations of ultrasonic probes in the art used for this application. Particularly, the present invention is directed towards providing a means to control, direct and focus the cavitation energy from a transversely vibrating ultrasonic probe by utilizing a sheath assembly extending circumferentially along the longitudinal axis of the probe. In accordance with the present invention, there is provided an ultrasonic probe operating in a transverse mode whereby the probe is cable of vibrating in a direction perpendicular to its longitudinal axis upon application of an ultrasonic frequency, capable of precisely focussing or directing the cavitation energy of the probe to defined regions within a blood vessel. The object of this invention can be accomplished by a transversely vibrating ultrasonic probe described in a co-application submitted by the applicants (###) the entirety of which is herein incorporated by reference.


Further in accordance with the invention, a sheath, a sleeve or other damping member provided with fenestrations is a sheath that is adapted circumferentially along the probe axis, thereby providing control over release of cavitation energy in specific regions along the probe axis. Non-fenestrated areas of the said sheath or sleeve effectively block cavitation energy emanating from the probe from such areas.


Still further in accordance with the invention, a sheath assembly comprising one or more sheaths may can be adapted to the ultrasonic probe, thereby providing a means of containing, focussing, and transmitting energy generated along the length of the probe to one or more defined locations. The sheaths of the present invention also provide the user with a means of protecting regions of tissue from physical contact with the probe. In one embodiment of the invention he sheaths also comprise a means for aspiration and irrigation of the region of probe activity, as well as a means of introducing a drug or compound to the site of probe activity.


In one aspect, a plurality of sheaths are used in combination to provide another level of precision control over the direction of cavitation energy to a tissue in the vicinity of the probe. In one embodiment of the invention, the sheath encloses a means of introducing fluid into the site of the procedure, and a means for aspirating fluid and tissue debris from the site of the procedure. In another aspect the sheath assembly further encloses a means of introducing a drug intravascularly that dissolves clots and prevents the recurrence of stenosis. The ultrasonic oscillation of the probe of the present invention will be used to facilitate the penetration of antithrombogenic agents into the vascular or luminal walls to inhibit restenosis. Preferred antithrombogenic agents include heparin, hirudin, hirulog, urokinase, streptokinase, tPA, and similar agents. In a further embodiment, the probe tip can be moved within the sheath. In yet another aspect, the irrigation and aspiration means, and the probe tip, can all be manipulated and repositioned relative to one another within the sheath. In another embodiment, the sheath is shaped in such a way that it may capture or grasp sections of tissue that can be ablated with the probe.


Still further in accordance with the invention, the sheath provides a guide for the probe tip, protecting tissues from accidental puncture by the sharp, narrow-diameter tip, or from destruction by energy emitted radially from the probe during introduction of the probe to the site. The sheath may be applied either to the probe tip prior to insertion of the probe into the patient, or pre-inserted into the patient prior to the insertion of the probe. The sheath of the present invention can be used to fix the location of one or more shapes relative to the nodes or anti-nodes of a probe acting in transverse action. The location of the reflective shapes can amplify the acoustical wave thereby magnifying the energy. This allows for the use of very small diameter probes which themselves would not have the requisite structural integrity to apply and translate acoustical energy into sufficient mechanical energy to enable ablation of tissues. The reflective shapes can also focus or redirect the energy, effectively converting a transverse probe emitting cavitation energy along its length, to a directed, side fire ultrasonic device.


In a still further aspect of the invention the probe emits transverse ultrasonic energy along its longitudinal axis that may be used to, for example, fragment abnormal cells on the surface of the body cavity which come within the sweep of the probe, or to clear obstructions and constrictions within vasculature or tissue lumen. The device is designed to have a small cross-sectional profile, which also allows the probe to flex along its length, thereby allowing it to be used in a minimally invasive manner. In one aspect, the probe be at least partially contained within the sheath to contain, focus, intensify, and direct the emitted cavitation energy to specific target tissue sites. In another embodiment of the invention, a plurality of sheaths are used in combination to provide another level of precision control over the direction of cavitation energy to a tissue in the vicinity of the probe.


Still further in accordance with the invention, the sheath encloses a means of introducing fluid into the site of the procedure, and a means for aspirating fluid and tissue debris from the site of the procedure. In a further embodiment, the probe tip can be moved within the sheath. In one aspect, the irrigation and aspiration means, and the probe tip, can all be manipulated and repositioned relative to one another within the sheath. In another aspect, the sheath is shaped in such a way that it may capture or grasp sections of tissue that may be ablated with the probe. In yet another embodiment, the sheath provides a guide for the probe tip, protecting tissues from accidental puncture by the sharp, narrow diameter tip, or from destruction by energy emitted radially from the probe. The sheath may be applied to the probe tip prior to insertion of the probe into the patient, or the sheath can be inserted into the patient prior to the insertion of the probe.


The sheath of the present invention can be used to fix the location of one or more shapes relative to the energy nodes or anti-nodes emitted by a transversely vibrating probe. The location of and the particular shape can modulate the energy emitted from the probe at one site, and communicate it to a distant site, for example, it may amplify the acoustical wave at one or more energetic anti-nodes, thereby increasing the energy emitted at the sheath's aperture. This allows for the use of very small diameter probes which themselves would not have the requisite structural integrity to apply and translate acoustical energy into sufficient mechanical energy to enable ablation of tissues. The reflective shapes can also focus or redirect the energy, effectively converting a transverse probe emitting cavitation energy along its length, to for example, a directed, “side-fire” ultrasonic device.





BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, like reference characters generally refer to the same parts throughout the different views. The drawings shown are not necessarily to scale, with emphasis instead generally being placed upon illustrating the principles of the invention.



FIG. 1 illustrates an exemplary ultrasonic device comprising the ultrasonic probe tip constructed in accordance with the principles of the present invention



FIG. 2 shows the areas of maximum vibrations (anti-nodes) and minimum vibrations (nodes) caused by transverse, vibration of probe and probe tip.



FIGS. 3
a-g show different configurations of sheaths comprising the sheath assembly adapted to the probe.



FIG. 4 shows a probe that is substantially contained within a sheath comprising a plurality of fenestrations.



FIG. 5 shows a probe that is substantially contained within a sheath assembly comprising a plurality of adjustable sheaths.



FIG. 6 shows a longitudinal cross-sectional view of the distal end of the probe comprising a central irrigation passage, lateral irrigation lumens and external aspiration channels.



FIG. 7 shows a transverse cross-sectional view of a portion of the probe illustrating the irrigation and aspiration channels.



FIG. 8 are longitudinal cross-sectional views of the distal end of the probe contained within sheaths incorporating angled reflective elements.



FIG. 9 are longitudinal cross-sectional views of the distal end of the probe contained within sheaths incorporating arctuate of reflective elements





DETAILED DESCRIPTION OF INVENTION

The following terms and definitions are used herein:


“Anti-node” as used herein refers to a region of maximum energy emitted by an ultrasonic probe on or proximal to a position along the probe.


“Cavitation” as used herein refers to shock waves produced by ultrasonic vibration, wherein the vibration creates a plurality of microscopic bubbles which rapidly collapse, resulting in molecular collision by water molecules which collide with force, thereby producing the shock waves.


“Cross-sectional diameter” as used herein refers to the diameter of the cylindrical regions of the probe, including the probe tip.


“Fenestration” as used herein refers to an aperture, window, opening, hole, or space.


“Node” as used herein refers to a region of minimum energy emitted by an ultrasonic probe on or proximal to a position along the probe.


“Probe” as used herein refers to a device capable of being adapted to an ultrasonic generator means, which is capable of propagating the energy emitted by the ultrasonic generator means along its length, and is capable of acoustic impedance causing transformation of ultrasonic energy into mechanical energy.


“Sheath” as used herein refers to an apparatus for covering, encasing, or shielding in whole or in part, a probe or portion thereof connected to an ultrasonic generation means.


“Transverse” as used herein refers to vibration of a probe at right angles to the axis of a probe. A “transverse wave” as used herein is a wave propagated along an ultrasonic probe in which the direction of the disturbance at each point of the medium is perpendicular to the wave vector.


“Tuning” as used herein refers to a process of adjusting the frequency of the ultrasonic generator means to select a frequency that establishes a standing wave along the length of the probe.


The present invention provides an ultrasonic medical device for tissue ablation. More particularly the present invention provides an ultrasonic device comprising a probe capable of vibrating ultrasonically in a transverse mode causing generation of cavitational energy circumferentially around the said probe, comprising a protective sheath assembly adapted over the probe that is capable of focussing, directing and modulating the cavitational energy emitted by the probe. The sheath assembly of the invention allows the user to optimize the tissue ablation efficiency of the probe to suit a particular medical procedure.


The probe of the invention is capable of removing tissue at sites wherein the probe makes actual contact with the tissue, and typically in a region that is radially disposed (approximately 2 mm) from the probe, that corresponds to the region of maximum cavitational energy or “anti-nodes” emanating perpendicular to the longitudinal axis of the probe. By eliminating the axial motion of the probe and allowing transverse vibrations only, fragmentation of large areas of tissue spanning the entire length of the probe due to generation of multiple cavitational anti-nodes along the probe length perpendicular to the probe axis. Since substantially larger affected areas within an occluded blood vessel can be denuded of the occluded tissue in a short time, actual treatment time using the transverse mode ultrasonic medical device according to the invention is greatly reduced as compared to methods using pilot art probes that primarily utilize longitudinal vibration (along probe axis) for tissue ablation. Because the thinnest region of the probe is capable of providing, multiple energy anti-nodes along its length, it is desirable to have a means of modulating this energy, thereby providing a precise way of delivering the energy selectively to desired locations, such as for example an occluded region within a blood vessel, while protecting nearby tissues both from the fragmenting energy and physical damage (for example, punctures) from the narrow diameter probe tip. The probe equipped with a sheath assembly such as that described herein, provides a means for modulating the intensity and direction of energy emitted from such a probe. Additionally, the probe equipped with the sheath assembly of the invention provides a more efficient, selective means of delivering energy from the probe to a specific tissue space, or tissue space, for example at the site of an occlusion within a blood vessel, causing rapid fragmentation and ablation of said tissue without detrimental effect other areas within the vessel.


Probes of the present invention are described in the Applicant's co-pending provisional applications U.S. Ser. Nos. 60/178,901 and 60/225,060 which further describe the design parameters for an ultrasonic probe operating in a transverse mode and the use of such a probe to remodel tissues. The entirety of these applications are herein incorporated by reference.


The present invention allows the selective application of cavitation energy emitted from an ultrasonic probe to tissue. The probe is adapted to an ultrasonic generator means that selectably provides energy over a frequency range of from about 20 kHz to about 80 kHz. In the currently preferred embodiment, the frequency of ultrasonic energy is from 20,000 Hertz to 35,000 Hertz. Frequencies in this range are specifically destructive of hydrated (water-laden) tissues, while substantially ineffective toward high-collagen connective tissue, or other fibrous tissues such as skin or muscle tissues. The amount of cavitation energy to be applied to a particular site requiring treatment is a function of the amplitude and frequency of vibration of the probe, as well as the longitudinal length of the probe tip, the proximity of the tip to a tissue, and the degree to which the probe tip is exposed to the tissues. Control over this last variable can be effectuated through the sheath of the present invention.


A significant advantage of the ultrasonic medical device of the invention is that it physically destroys and removes undesired tissue through the mechanism of cavitation, which is non-thermal. As a consequence, the complications which are arise from thermal destruction or necrosis of tissue are not observed. The increase in local temperature is most likely a result of the heating of the probe. By using the probe contained within a sheath of the present invention the probe is substantially contained and isolated from direct contact with the tissues, thereby enabling destruction of tissues with only a small increase in local temperature, about 7° C. from normal body temperature. The use of a sheath further diminishes or prevents the local temperature rise. Accordingly, In one embodiment, the sheath of the present invention provides a means of insulating surrounding tissue from the thermal side effects of the ultrasonic probe.


The length and diameter of the sheath used in a particular surgical procedure is dependent on the type of probe used, the degree to which the probe length will be inserted into the patient, and the degree of shielding that is required based on the specific areas to be treated. For example, in an application whereby prostate tissue is removed via an intra-urethral route with the ultrasonic probe of the present invention, the sheath must be of a sufficient length to protect the tissue of the urethra, of a sufficient outside diameter to facilitate insertion of the sheath into the urethra, and a sufficient inside diameter capable of accepting the probe. By contrast, for tissue remodeling near, for example, the eye, a probe useful for such a procedure would be significantly shorter and of a significantly smaller diameter, and as such, so would the sheath. The exact dimensions of the sheath including its length and diameter is determined by requirements of a specific medical procedure. Similarly, as illustrated in FIGS. 3 and 4, the position and size of the sheath aperture 111, or number and positions of the fenestrations 111, or the presence of a bevel on the sheath terminus 129 to provide a means for tissue manipulations, will likewise be determined by the type of procedure, and the requirements of the particular patient.


In one aspect of the invention, as shown in FIG. 5, the sheath comprises an inner sheath 121 and an outer sheath 108. The outer sheath may be connected to a retraction trigger (not shown), by one or more articulation means, such as wires, which is capable of moving the outer sheath with respect to the inner sheath. Each wire comprises a first end and a second end. The first end is affixed to the outer sheath 108, while the second end is affixed to a retraction trigger. When the outer sheath 108 is slid back away from the terminus of the inner sheath 121 the tissues are exposed to cavitation energy emitted by the probe.


In another embodiment, the sheath is flexible. Articulation wires (not shown) comprising two ends, are connected to the sheath and an articulation handle. When the articulation handle is manipulated, for example, pulled axially inward, the flexible sheath will bend or articulate in a bending or articulation direction A, thereby causing the ultrasonic probe to bend or articulate in articulation direction A. In this way, the ultrasonic probe can be used to reach locations that are not axially aligned with the lumen or vessel through which the sheath and probe are inserted.


A particular advantage of the ultrasonic probe operating in transverse mode is that the efficient cavitation energy produced by the probe disintegrates target tissue to small particles of approximately 5 microns in diameter. Because of the operation of the probe, tissue debris created at the probe tip is propelled in a retrograde direction from the probe tip. Accordingly, in another embodiment of the invention, the sheath provides at least one aspiration channel, which can be adapted to a vacuum or suction device, to remove the tissue debris created by the action of the probe. The aspiration channel can be manufactured out of the same material as the sheath provided it is of a sufficient rigidity to maintain its structural integrity under the negative pressure produced by the aspiration means, for example a vacuum pump or other source of negative pressure. Such an aspiration channel is provided either inside the lumen of the sheath, or along the exterior surface of the sheath, or both. In these embodiments, the aspiration channel can be a second hollow sheath nested within the first sheath, or the aspiration channel can be formed in the body of the sheath. A preferred embodiment is shown in FIGS. 6 and 7, whereby the probe 22 itself has one or more grooves defining one or more aspiration channels 60, and aspiration of tissue debris is effectuated along the probe length between the interior surface of the sheath and the exterior surface of the probe, as directed by the aspiration channels and by retrograde flow from the probe action. FIG. 6 shows a longitudinal cross-section of a portion of an ultrasonic probe 22 and tip 23 according to one embodiment of the invention, comprising a central irrigation passage 17 and lateral irrigation lumens 19, as well as external aspiration channels 60. The sheath, not shown, would surround the probe.


In another embodiment, the sheath of the present invention comprises an irrigation channel. The sheath is adapted to an irrigation means, for example, a peristaltic pump or other such device for delivering liquids under controlled flow rates and pressures, and the sheath directs fluid to the location of the probe. The irrigation channel can be manufactured out of the same material as the sheath provided it is of a sufficient rigidity to maintain its structural integrity under the positive pressure produced by the flow of fluid produced by the irrigation means. Such an irrigation channel is provided either inside the lumen of the sheath, or along the exterior surface of the sheath, or both. In these embodiments, the irrigation channel can be a second hollow sheath nested within the first sheath, or the irrigation channel can be formed in the body of the sheath. In one embodiment, the probe itself has one or more grooves defining irrigation channels, and fluid is directed along the probe length between the interior surface of the sheath and the exterior surface of the probe, as directed by the irrigation channels. In this embodiment, irrigation fluids provide a means of cooling the probe. The sheath itself, or an irrigation sheath contained within the first sheath can provide a means of introducing a drug or pharmaceutical formulation to the site of probe activity. For example, anti-thrombolytic drugs such as heparin, streptokinase, tPA, urokinase, hirulog, or hirudin may be introduced to the site of a vascular occlusion through the sheath. The ultrasonic energy further provides a means for assisting the drug in penetrating the occlusion.


In yet another embodiment, the sheath of the present invention further comprises both an irrigation and an aspiration channel. As in the above embodiments, the channels may be located within the sheath lumen, or exterior to the sheath, or a combination of the two, and can be proximal or distal to the other channel provided they are not in direct communication. Likewise, in these embodiments the probe itself has a plurality of grooves defining aspiration channels and irrigation channels, and fluid is directed along the probe length between the interior surfaces of the sheaths and the exterior surface of the probe, as directed by the aspiration and irrigation channels. In another aspect of the invention, the sheath comprises a means for directing, controlling, regulating, and focussing the cavitation energy emitted by the probe, an aspiration means, an irrigation means, or any combination of the above.


In yet another embodiment, as shown in FIG. 8, the sheath is a device that allows for the manipulation of tissues, comprising a surface that is capable of manipulating tissues near the site of the probe. In this aspect, the terminus of the sheath may be closed, such that the sheath insulates tissues from the destructive energy emitted by the probe and can be used to push tissues away from the aperture 111, thereby allowing proximal tissues to be exposed to the probe 22 and 23. Alternatively, the sheath comprises a beveled or arcutate surface at the sheath terminus 129, capable of providing a means for hooking, grasping, or otherwise holding a tissue in proximity to the probe 22 and 23. In another embodiment, the sheath allows for the introduction of another surgical device, for example, flexible biopsy forceps, capable of manipulating tissues into a tissue space, such that the surgical device can hold the tissue in proximity with the probe.


In a further embodiment, the internal surface of the sheath provides a means to amplify or focus cavitation energy from the probe 22. In this aspect, the interior surface of the sheath comprises at least one structure or reflective element 118, that extends into the sheath lumen. The reflective element maybe planar, or arcutate, or a combination of these shapes. Reflective elements of the present invention may be fabricated from the same material as the sheath, or may use different materials that optimize the reflective properties of the elements. Since the cavitation energy reaches a maximum at anti-nodes along the probe, the interval of the anti-nodes being determined by the ultrasonic frequency at which the generator operates, the spacing of the reflective elements in the sheath is determined by the intended operating frequency of the ultrasonic device. Similarly, the number of anti-nodes along the probe 22, is determined by the length of the probe and the frequency. As such, the number of reflective elements is determined by the length of the probe and the operating frequency. For example, an ultrasonic device operating at a frequency of approximately 25 kHz employing a probe with a length at the thinnest interval 22 of about 3 centimeters, will display about seven anti-nodes approximately 2 millimeters wide, spaced about 2 millimeters apart. Energy will radiate circumferentially around the probe at these anti-nodes. A sheath useful with such a probe would comprise, for example but not limited to, a cylindrical sheath about at least 3 centimeters in length further comprising seven reflective elements, approximately 2 millimeters wide, spaced about 2 millimeters apart, positioned with respect to the probe such that the reflective elements 118, are centered over the anti-nodes. Since the energy emitted by the probe radiates circumferentially from an anti-node, the reflective elements can extend radially from the interior, wall of the sheath into the sheath lumen, for example, 270 degrees around the interior of the sheath, while the remaining 90 degrees has no reflective element and thereby provides a means for channeling the cavitation energy from the anti-node to a position distal to the anti-node. The channeling means of the present example maybe a region where no reflective element is present, or where the shape or angle is altered compared to the reflective element, or any other such means of directing energy from the area of the anti-node to a position distal to the anti-node.


The sheath of the present invention may comprise a means of viewing the site of probe action. This may include an illumination means and a viewing means. In one embodiment, the sheath of the present invention comprises a means for containing or introducing (if external to the sheath) an endoscope, or similar optical imaging means. In another embodiment of the invention, the ultrasound medical device is used in conjunction with an imaging system, for example, MRI, or ultrasound imaging—in particular color ultrasound. In this embodiment, the action of the probe echogenically produces a pronounced and bright image on the display. The sheath in this embodiment shields the probe, thereby reducing the intensity of the probe image and enhancing the resolution of the image by decreasing the contrast between the vibrating probe and the surrounding tissues.


In yet another embodiment, the sheath assembly of the present on may be provided along with an ultrasonic probe in the form of a kit. In this aspect, the probe for a particular surgical procedure is provided, along with the correct sheath, as well as instructions for assembling and tuning the probe, and the appropriate frequency range for the procedure. The probe and sheath may be packaged preassembled, such that the probe is already contained within the sheath and the respective position of the probe within the sheath is optimized such that any reflective elements in the sheath would be correctly aligned with the prospective position of the anti-nodes for a given frequency, the kit further comprising instructions for the appropriate frequency. The kit may further comprise packaging whereby the probe and sheath are pre-sterilized, and sealed against contaminants. In a preferred embodiment, the probe and sheath are provided in a container that complies with regulations governing the storage, handling, and disposal of sharp medical devices. Such a container is capable of receiving and securing the probe and sheath before and after use. In one aspect, the sharps container provides a means of affixing the probe and sheath assembly to an ultrasonic medical device without direct manipulation of the probe and sheath assembly, and a means for removing the assembly from the ultrasonic medical device after use. In another aspect, the kit comprises a probe and sheath assembly contained within a sterile sharps container that further comprises a single use locking means, whereby the probe and sheath assembly is affixed to the ultrasonic medical device solely through the sharps container, are removed from device solely through the container, and once removed can not be re-extracted from the sharps container.


Referring now to FIG. 1, a transverse mode ultrasonic medical device comprising an elongated probe 6 which is coupled to a device providing a source or generation means for the production of ultrasonic energy (shown in phantom in the Figure as 66) constructed in accordance with the present invention is illustrated. The generation source may or may not be a physical part of the device itself. The probe 6 transmits ultrasonic energy received from the generator along its length. The probe is capable of engaging the ultrasonic generator at one terminus with sufficient restraint to form an acoustical mass that can propagate the ultrasonic energy provided by the generator. The other terminus of the probe comprises a tip 22, which has a small diameter, enabling the tip to flex along its longitude. In one embodiment of the invention, the probe diameter decreases at defined regional or segment intervals 14, 18, 20, and 22. Energy from the generator is transmitted along the length of the probe, causing the probe segments 22 and 23 at the distal end to vibrate in a direction that is transverse to the probe longitudinal axis. In this embodiment, one of the probe intervals 18 has at least one groove 45 for engaging the locking assembly of a probe disposal container.


Referring now to FIG. 2, the terminal segment 22 and tip 23 of the probe are illustrated, wherein transverse vibration caused by application of ultrasonic energy to the probe generates alternating areas of maximum vibration, or “anti-nodes” 24, along the length of the probe segment 22 and tip 23, and “nodes,” or areas of minimum vibration 25, at repeating intervals along said segment and tip. The number of anti-nodes, and their spacing along the probe depends on the frequency of the energy produced by the ultrasonic generator, while the separation of nodes and anti-nodes is a function of harmonic intervals of the frequency, and can be affected by tuning the probe. In a properly tuned probe, the anti-nodes will be found at a position exactly one half of the distance between the nodes. Tissue-destroying effects of the device are not limited to regions coming into direct contact with probe tip 23, but rather, as the probe is moved through the area where ablation is desired, tissue is removed in areas adjacent to the multiplicity of anti-nodes produced along the entire length of the probe. The magnitude of the cavitation energy produced by the probe tip is such that it extends outward from the probe tip at the anti-nodes from about 1-2 millimeters.


Referring now to FIGS. 3a-g, sheath assemblies comprising different configurations of dampening sheaths for the ultrasonic probe 6 are illustrated. FIG. 3a shows a transverse mode probe 6 is shown comprising a semi-cylindrical sheath 107, which partially contains the probe. For purposes of illustration, the probe 6 is visible beneath the sheath. The sheath 107 is of a sufficient diameter, so as to at least partially encompass the probe. In the semi-cylindrical embodiment shown, the circumference of the sheath is approximately 180 degrees, and the length is sufficient to span a plurality of intervals 20 and 22 over the probe. FIG. 3b shows a semi-cylindrical sheath 107 (also shown in FIG. 2), and a second concentric sheath 108 that is cylindrical, and is capable of containing the first sheath 107, as well as the probe 6. FIG. 3c shows the sheath 121 having a cylindrical structure of a sufficient diameter to contain the probe 6, made visible for the purpose of illustration. Sheath 121 comprises at least one fenestration 111, which allows the cavitation energy emitted from the probe tip to be communicated to an area outside the sheath, through the said fenestration; probe energy from areas wherein the probe is not exposed by a fenestration is contained by the sheath. FIG. 3d shows the hollow cylindrical sheath 121 containing a plurality of arcutate fenestrations 111. FIG. 3e illustrates a longitudinal view of probe 6 contained within a sheath 121 which comprises a plurality of arcutate fenestrations 111, and at least one acoustic reflective element 122, that is adapted to the interior surface of the sheath. FIG. 3f shows a sheath 121 further comprising two semi-cylindrical halves 109, each half connected to the other by one or more connecting means 113. The probe 6 is capable of being substantially contained within the sheath. The cavitation energy generated by the probe tip 22 is contained by the semi-cylindrical halves 109, where they occlude the probe tip. FIG. 3g illustrates a sheath further comprising of at least two cylinders 104, each cylinder connected to the other by at least one connecting means 113. The probe 6 is capable of being substantially contained within the sheath. The cavitation energy generated by the probe tip 22 is contained by cylinders 104, where they occlude the probe tip.


Referring now to FIG. 4, a segment 20 of a probe is substantially contained in a sheath 121 comprising a plurality of fenestrations 111. Release of cavitation energy emitted by the probe 20, to the environment is controlled by sheath 121 and is communicated to the outside of the sheath through the fenestrations.


Referring now to FIG. 5, the distal end of the probe of ultrasonic medical device contained in a sheath assembly is illustrated. The probe 6 is substantially contained within a cylindrical sheath 121 capable of modulating the energy omitted by an active probe, and shielding tissues from puncture from a sharp probe tip. The sheath 121 shown in this illustration has been modified such that one of the terminal ends of the sheath is substantially open, defining a fenestration or aperture 111, which exposes the probe tip 22 and 23. The terminus of the sheath 129 is shaped to provide a means for manipulating tissue to bring it into proximity with the probe 22 and 23. A second concentric cylindrical sheath 108 which surrounds a portion of the first sheath 121, that can be manipulated longitudinally along the first sheath to provide a means for modulating the exposure of the probe tip 22 and 23 by partial closure of the aperture 111, thereby modulating the cavitation energy emitted by the probe to which occlusion materials will be exposed.


Referring now to FIG. 6, a longitudinal cross-section of a portion of an ultrasonic probe tip 22 and 23 is shown, comprising a central irrigation passage 17, lateral irrigation lumens 19, and as external aspiration channels 60.


Referring now to FIG. 7, a transverse cross-sectional view of a portion of the ultrasonic probe shown. The probe 6 comprises a plurality of arcutate channels 60 that extend over the longitudinal length of the probe tip, providing a conduit for irrigation and or aspiration of tissue debris and fluid.


Referring now to FIG. 8, sheath comprising a fenestration 111 allowing communication of the cavitation energy emitted by the probe to the outside of the sheath is shown. The interior of the sheath further comprises reflective elements 118, shown as a plurality planar surfaces that extend from the interior wall of the sheath into the lumen, thereby providing a means for focusing and redirecting cavitation energy emitted by the probe tip. In embodiment, the terminus of the sheath 129 is shaped to provide a tissue manipulation means.


Referring now to FIG. 9, a sheath comprising a fenestration 111 allowing communication of the cavitation energy emitted by the probe to the outside of the sheath is shown. The interior of sheath 121 containing the probe 22 and 23 comprises reflective elements 118 that are arcuate, and contain a plurality of fenestrations 111.


Sheath materials useful for the present invention include any material with acoustical or vibrational dampening properties capable of absorbing, containing, or dissipating the cavitation energy emitted by the probe tip. Such materials must be capable of being sterilized by, for example, gamma irradiation or ethylene oxide gas (ETO), without losing their structural integrity. Such materials include but are not limited to, plastics such as polytetrafluoroethylene (PTFE), polyethylene, polypropylene, silicone, polyetherimide, or other such plastics that are used in medical procedures. Ceramic materials can also be used, and have the added benefit that they may be sterilized by autoclaving. Combinations of the aforementioned materials can be used depending on the procedure, for example as in the sheath of FIG. 5, a ceramic sheath 121 can be used in combination with a moveable PTFE outer sheath 108. Alternatively a single sheath may employ two or more materials to give the desired combination of strength and flexibility, for example, the sheath may comprise a rigid ceramic section distal to the probe tip 23 and a more flexible plastic section proximal to the tip, capable of flexing with the probe 22. In the currently preferred embodiment of the invention, PTFE is used to fabricate a strong, flexible, disposable sheath that is easily sterilized by irradiation or ETO gas.


It should be obvious to those of ordinary skill in the art that the individual features described herein may be combined. Variations, modifications, and other implementations of what is described herein will occur to those of ordinary skill in the art without departing from the spirit and scope of the invention as claimed. Accordingly, the invention is to be defined not by the preceding illustrative description but instead by the spirit and scope of the following claims.

Claims
  • 1. An ultrasonic medical device for tissue ablation comprising: an elongated probe having a proximal end, a distal end and at least two regions of differing cross sectional dimension, wherein a length of the elongated probe is configured to oscillate in a direction transverse to a longitudinal axis of the elongated probe to emit transverse ultrasonic energy along the length of the elongated probe so that a plurality of transverse nodes and transverse anti-nodes are formed along the length of the elongated probe; anda sheath assembly at least partially surrounding the elongated probe, the sheath assembly comprising at least one sheath defining a fenestration between a proximal and distal end of the at least one sheath, the at least one sheath being configured to substantially dampen ultrasonic energy such that ultrasonic energy delivered by the elongated probe is focused toward a region adjacent the fenestration.
  • 2. The device of claim 1, wherein the sheath assembly covers at least a portion of the elongated probe, the sheath assembly comprising a longitudinally extending structural wall that defines a longitudinally extending hollow interior for accommodating at least a portion of the elongated probe, wherein the longitudinally extending structural wall of the sheath assembly is substantially self supporting so that the longitudinally extending structural wall substantially maintains a same shape with the elongated probe disposed in the longitudinally extending hollow interior as without the elongated probe disposed in the longitudinally extending hollow interior.
  • 3. The device of claim 1, wherein the sheath assembly is constructed to substantially prevent a transmission of cavitational energy generated by the elongated probe to a surrounding environment.
  • 4. The device of claim 1, wherein the sheath assembly further comprises one or more devices capable of manipulating a tissue.
  • 5. The device of claim 1, wherein the sheath assembly further comprises at least one reflective element configured to reflect ultrasonic energy.
  • 6. The device of claim 1, wherein the sheath assembly further comprises at least one irrigation channel.
  • 7. The device of claim 1, wherein the sheath assembly further comprises at least one aspiration channel.
  • 8. The device of claim 1, wherein the sheath assembly further comprises at least one channel for delivering a therapeutic agent therethrough.
  • 9. The device of claim 1, wherein the sheath assembly is adapted for use with an imaging system.
  • 10. A method of modulating, focusing and directing a cavitational energy emitted from an ultrasonic probe vibrating in a direction transverse to a longitudinal axis of the ultrasonic probe for tissue ablation comprising: enclosing at least a portion of the ultrasonic probe within a sheath assembly comprising a sheath defining at least one fenestration between a proximal end and a distal end of the sheath;inserting the ultrasonic probe into a blood vessel;guiding the ultrasonic probe and the sheath assembly into the blood vessel and to a site of an occlusion;positioning the ultrasonic probe and the sheath assembly such that the at least one fenestration is in proximity with the occlusion;providing an ultrasonic excitation signal to the ultrasonic medical device and transferring the ultrasonic excitation signal along a length of the ultrasonic probe to a flexible probe tip, thereby causing a transverse vibration of the length of the ultrasonic probe and the flexible probe tip and a generation of a plurality of transverse nodes and anti-nodes of the cavitational energy along the length of the ultrasonic probe and the flexible probe tip; andcontrolling a selective transmission of cavitational energy through the at least one fenestration in the sheath, thereby directing the cavitational energy in an area of the occlusion within the blood vessel to cause fragmentation of the occlusion.
  • 11. The method of claim 10, wherein the sheath assembly is capable of partially shielding tissue at a site of a surgical procedure from the ultrasonic probe.
  • 12. The method of claim 10, further comprising removing at least one fragment of the occlusion through an aspiration conduit of the sheath assembly.
  • 13. The method of claim 10, further comprising supplying an irrigating fluid to the site of the occlusion through an irrigation conduit of the sheath assembly.
  • 14. The method of claim 10, further comprising delivering a therapeutic agent through a conduit of the sheath assembly.
  • 15. The method of claim 10, further comprising positioning the ultrasonic probe proximal to the occlusion using an imaging system.
  • 16. The method of claim 10, comprising manipulating tissue with a tissue manipulation device of the sheath assembly.
  • 17. The method of claim 10, further comprising shielding an ultrasound energy emitted from the ultrasonic probe with the sheath assembly, and visualizing a surgical site with an ultrasound imaging system, the shielding of the ultrasound energy increasing the resolution of the surgical site visualized by the ultrasound imaging system.
  • 18. The method of claim 10, further comprising introducing the sheath assembly from an exterior of a patient to the site of the occlusion, and introducing the ultrasonic probe into the sheath assembly and guiding the ultrasonic probe to a surgical site.
  • 19. A medical device, comprising: an ultrasonic probe configured to emit ultrasonic energy transversely along a portion of the ultrasonic probe; anda sheath comprising a proximal end and a distal end, the sheath at least partially surrounding the ultrasonic probe and defining a fenestration between the proximal and distal ends of the sheath, the sheath being configured to substantially dampen ultrasonic energy such that ultrasonic energy delivered by the medical device is focused toward a region adjacent the fenestration.
  • 20. The medical device of claim 19, wherein the sheath defines a plurality of fenestrations between the proximal and distal ends of the sheath.
  • 21. The medical device of claim 19, wherein the fenestration extends from a proximal end of the sheath to a distal end of the sheath.
  • 22. The medical device of claim 19, further comprising at least one reflective element disposed on an interior surface of the sheath.
  • 23. The medical device of claim 19, wherein the sheath is at least partially surrounded by a second, retractable sheath.
  • 24. The medical device of claim 19, wherein the sheath is constructed to substantially prevent ultrasonic energy from passing therethrough.
  • 25. The medical device of claim 24, wherein the sheath comprises one or more materials that are capable of dissipating ultrasonic energy.
US Referenced Citations (840)
Number Name Date Kind
168975 Farmer Oct 1875 A
323762 White Aug 1885 A
404319 Taylor May 1889 A
414090 Taylor Oct 1889 A
1045326 Ruflin Nov 1912 A
1239451 Belz Sep 1917 A
1779478 Leech Oct 1930 A
1861769 Wappler Jun 1932 A
2199602 Wright May 1940 A
2242120 Gardiner May 1941 A
2270922 Bechmann et al. Jan 1942 A
2321358 Bokovoy Jun 1943 A
2514080 Mason Jul 1950 A
2742076 Klein Apr 1956 A
2838695 Thurston Jun 1958 A
2843176 Franck Jun 1958 A
2917691 De Prisco et al. Dec 1959 A
2990616 Balamuth et al. Jul 1961 A
3056698 Kleesattel et al. Oct 1962 A
3089790 Balamuth et al. May 1963 A
3113225 Kleesattel et al. Dec 1963 A
3132548 Livermont May 1964 A
3133351 von Seggern May 1964 A
3202021 Livermont Aug 1965 A
3241780 Kitselman Mar 1966 A
3304449 Pohlman et al. Feb 1967 A
3315663 Goldfarb Apr 1967 A
3401446 Obeda et al. Sep 1968 A
3433226 Boyd Mar 1969 A
3438824 Balamuth Apr 1969 A
3486361 Vaneman et al. Dec 1969 A
3524085 Shoh Aug 1970 A
3526219 Balamuth Sep 1970 A
3528410 Banko Sep 1970 A
3565062 Kuris Feb 1971 A
3589363 Banko Jun 1971 A
3614484 Shoh Oct 1971 A
3660186 Sager et al. May 1972 A
3683736 Loose Aug 1972 A
3763680 Godfrey et al. Oct 1973 A
3805787 Banko Apr 1974 A
3809977 Balamuth et al. May 1974 A
3840932 Balamuth et al. Oct 1974 A
3853130 Sheridan Dec 1974 A
3861391 Antonevich et al. Jan 1975 A
3890977 Wilson Jun 1975 A
3906954 Baehr et al. Sep 1975 A
3939033 Grgach et al. Feb 1976 A
3955662 Thackston May 1976 A
3962898 Tillmann Jun 1976 A
3967621 Schwarz Jul 1976 A
3980906 Kuris et al. Sep 1976 A
3988782 Dardik et al. Nov 1976 A
3990452 Murry et al. Nov 1976 A
3991929 Smith Nov 1976 A
4011474 O'Neill Mar 1977 A
4012174 Seibel et al. Mar 1977 A
4012647 Balamuth et al. Mar 1977 A
4044174 Carr Aug 1977 A
4063557 Wuchinich et al. Dec 1977 A
4069541 Williams et al. Jan 1978 A
4083996 Tanaka et al. Apr 1978 A
4136700 Broadwin et al. Jan 1979 A
4143130 Imondi et al. Mar 1979 A
4144646 Takemoto et al. Mar 1979 A
4157396 Tanaka et al. Jun 1979 A
4164524 Ward et al. Aug 1979 A
4169984 Parisi Oct 1979 A
4174410 Smith Nov 1979 A
4178935 Gekhman et al. Dec 1979 A
4203429 Vasilevsky et al. May 1980 A
4203444 Bonnell et al. May 1980 A
4223676 Wuchinich et al. Sep 1980 A
4225803 Goof Sep 1980 A
4236510 Hatter et al. Dec 1980 A
4248232 Engelbrecht et al. Feb 1981 A
4265928 Braun May 1981 A
4280233 Raab Jul 1981 A
4300564 Furihata Nov 1981 A
4311147 Hausler Jan 1982 A
4315181 Holze, Jr. Feb 1982 A
4316465 Dotson, Jr. Feb 1982 A
4326903 Summo Apr 1982 A
4334168 Besson et al. Jun 1982 A
4335426 Maxwell et al. Jun 1982 A
4352570 Firth Oct 1982 A
4356590 Goldsmith Nov 1982 A
4363992 Holze, Jr. Dec 1982 A
4368410 Hance et al. Jan 1983 A
4385413 Goldsmith May 1983 A
4393734 Thorn et al. Jul 1983 A
4395392 Wolgemuth Jul 1983 A
4399003 Sarig et al. Aug 1983 A
4414045 Wang et al. Nov 1983 A
4425115 Wuchinich Jan 1984 A
4428748 Peyman et al. Jan 1984 A
4445509 Auth May 1984 A
4447455 Madaus et al. May 1984 A
4462242 Morgenthaler Jul 1984 A
4467678 Lindholm Aug 1984 A
4474180 Angulo Oct 1984 A
4479585 Sandhaus Oct 1984 A
4480642 Stoy et al. Nov 1984 A
4483571 Mishiro Nov 1984 A
4486680 Bonnet et al. Dec 1984 A
4493694 Wuchinich Jan 1985 A
4498025 Takahashi Feb 1985 A
4504264 Kelman Mar 1985 A
4516398 Wuchinich May 1985 A
4523122 Tone et al. Jun 1985 A
4526571 Wuchinich Jul 1985 A
4529115 Renshaw et al. Jul 1985 A
4530138 Ritter Jul 1985 A
4534819 Payet et al. Aug 1985 A
4535659 Yang Aug 1985 A
4535759 Polk et al. Aug 1985 A
4571520 Saito et al. Feb 1986 A
4572041 Rissmann Feb 1986 A
4576177 Webster, Jr. Mar 1986 A
4583365 John Apr 1986 A
4587958 Noguchi et al. May 1986 A
4589415 Haaga May 1986 A
4601705 McCoy Jul 1986 A
4603694 Wheeler Aug 1986 A
4605454 Sayovitz et al. Aug 1986 A
4607185 Elbert et al. Aug 1986 A
4609368 Dotson, Jr. Sep 1986 A
4620545 Shene et al. Nov 1986 A
4633119 Thompson Dec 1986 A
4634420 Spinosa et al. Jan 1987 A
4642509 Kumada Feb 1987 A
4643717 Cook et al. Feb 1987 A
4647336 Coenen et al. Mar 1987 A
4647871 Turner, Jr. Mar 1987 A
4651043 Harris et al. Mar 1987 A
4652785 Gabriel et al. Mar 1987 A
4652786 Mishiro Mar 1987 A
4655104 Blattner Apr 1987 A
4663556 Kumada May 1987 A
4676975 McGary et al. Jun 1987 A
4678993 Vinnemann et al. Jul 1987 A
4688454 Scull Aug 1987 A
4690722 Flood Sep 1987 A
4692139 Stiles Sep 1987 A
4696299 Shene et al. Sep 1987 A
4702236 Tarabichy et al. Oct 1987 A
4704131 Noishiki et al. Nov 1987 A
4704573 Turner, Jr. Nov 1987 A
4708127 Abdelghani Nov 1987 A
4713132 Abel et al. Dec 1987 A
4715078 Howard et al. Dec 1987 A
4718907 Karwoski et al. Jan 1988 A
4730614 Lacruche et al. Mar 1988 A
4732152 Wallsten et al. Mar 1988 A
4732156 Nakamura Mar 1988 A
4735625 Davidson Apr 1988 A
4738666 Fuqua Apr 1988 A
4738667 Galloway Apr 1988 A
4747820 Hornlein et al. May 1988 A
4748985 Nagasaki Jun 1988 A
4748986 Morrison et al. Jun 1988 A
4749437 Welter Jun 1988 A
4750488 Wuchinich et al. Jun 1988 A
4750902 Wuchinich et al. Jun 1988 A
4751916 Bory Jun 1988 A
4756304 Watanabe Jul 1988 A
4756309 Sachse et al. Jul 1988 A
4758222 McCoy Jul 1988 A
4758293 Samida Jul 1988 A
4762668 Loose et al. Aug 1988 A
4770730 Abe Sep 1988 A
4771202 Takahashi Sep 1988 A
4771782 Millar Sep 1988 A
4791915 Barsotti et al. Dec 1988 A
4794912 Lia Jan 1989 A
4823723 Brooks Apr 1989 A
4823783 Willhite, Jr. et al. Apr 1989 A
4825851 Cocks et al. May 1989 A
4828052 Duran et al. May 1989 A
4830002 Semm May 1989 A
4834102 Schwarzchild et al. May 1989 A
4838853 Parisi Jun 1989 A
4838859 Strassmann Jun 1989 A
4844081 Northeved et al. Jul 1989 A
4846161 Roger Jul 1989 A
4846174 Willard et al. Jul 1989 A
4846790 Hornlein et al. Jul 1989 A
4850358 Millar Jul 1989 A
4862573 Kelson et al. Sep 1989 A
4866491 Solomon et al. Sep 1989 A
4867141 Nakada et al. Sep 1989 A
4870953 DonMicheal et al. Oct 1989 A
4872333 Burnand Oct 1989 A
4873969 Huebsch Oct 1989 A
4877037 Ko et al. Oct 1989 A
4880011 Imade et al. Nov 1989 A
4881761 Hornlein et al. Nov 1989 A
4882777 Narula Nov 1989 A
4885499 Ueha et al. Dec 1989 A
4886060 Wiksell Dec 1989 A
4886491 Parisi et al. Dec 1989 A
4892089 Cocks et al. Jan 1990 A
4904391 Freeman Feb 1990 A
4907572 Borodulin et al. Mar 1990 A
4909789 Taguchi et al. Mar 1990 A
4917104 Rebell Apr 1990 A
4920954 Alliger et al. May 1990 A
4922902 Wuchinich et al. May 1990 A
4924863 Sterzer May 1990 A
4931047 Broadwin et al. Jun 1990 A
4931049 Klimas Jun 1990 A
4936281 Stasz Jun 1990 A
4960410 Pinchuk Oct 1990 A
4961424 Kubota et al. Oct 1990 A
4962755 King et al. Oct 1990 A
4963151 Ducheyne et al. Oct 1990 A
4966131 Houghton et al. Oct 1990 A
4966148 Millar Oct 1990 A
4974581 Wiksell Dec 1990 A
4978333 Broadwin et al. Dec 1990 A
4979952 Kubota et al. Dec 1990 A
4986808 Broadwin et al. Jan 1991 A
4989583 Hood Feb 1991 A
4989588 Kubota et al. Feb 1991 A
5003965 Talish et al. Apr 1991 A
5003990 Osypka Apr 1991 A
5015221 Smith May 1991 A
5015227 Broadwin et al. May 1991 A
5017379 Lemelson May 1991 A
5019083 Klapper et al. May 1991 A
5024234 Leary et al. Jun 1991 A
5026387 Thomas Jun 1991 A
5027792 Meyer Jul 1991 A
5040548 Yock Aug 1991 A
5045054 Hood et al. Sep 1991 A
5046497 Millar Sep 1991 A
5049157 Mittelmeier et al. Sep 1991 A
5054492 Scribner et al. Oct 1991 A
5055101 McCoy Oct 1991 A
5057106 Kasevich et al. Oct 1991 A
5057119 Clark et al. Oct 1991 A
5057182 Wuchinich Oct 1991 A
5058570 Idemoto et al. Oct 1991 A
5059210 Clark et al. Oct 1991 A
5061273 Yock Oct 1991 A
5062827 Wiksell Nov 1991 A
5064765 Karasikov et al. Nov 1991 A
5069664 Guess et al. Dec 1991 A
5076276 Sakurai et al. Dec 1991 A
5102403 Alt Apr 1992 A
5106741 Marotti et al. Apr 1992 A
5108238 Ewing Apr 1992 A
5109830 Cho May 1992 A
5112300 Ureche May 1992 A
5116343 Ams et al. May 1992 A
5122122 Allgood Jun 1992 A
5123903 Quaid et al. Jun 1992 A
5127405 Alcala et al. Jul 1992 A
5129914 Choi Jul 1992 A
5139496 Hed Aug 1992 A
5139509 Fischer et al. Aug 1992 A
5147316 Castillenti Sep 1992 A
5151085 Sakurai et al. Sep 1992 A
5151099 Young et al. Sep 1992 A
5152200 Kaplan Oct 1992 A
5152748 Chastagner Oct 1992 A
5156143 Bocquet et al. Oct 1992 A
5163421 Bernstein et al. Nov 1992 A
5167619 Wuchinich Dec 1992 A
5169386 Becker et al. Dec 1992 A
5171387 Wuchinich Dec 1992 A
5175492 Wong et al. Dec 1992 A
5176141 Bom et al. Jan 1993 A
5176677 Wuchinich Jan 1993 A
5180363 Idemoto et al. Jan 1993 A
5190517 Zieve et al. Mar 1993 A
5193525 Silverstein et al. Mar 1993 A
5195955 Don Michael Mar 1993 A
5201315 Griffith Apr 1993 A
5201316 Pomeranz et al. Apr 1993 A
5203338 Jang Apr 1993 A
5209719 Baruch et al. May 1993 A
5217465 Steppe Jun 1993 A
5221282 Wuchinich Jun 1993 A
5222937 Kagawa Jun 1993 A
5222974 Kensey et al. Jun 1993 A
5231080 Scholkens Jul 1993 A
5231994 Harmjanz Aug 1993 A
5232451 Freitas et al. Aug 1993 A
5235964 Abenaim Aug 1993 A
5240437 Christian Aug 1993 A
5243997 Uflacker et al. Sep 1993 A
5248296 Alliger Sep 1993 A
5249580 Griffith Oct 1993 A
5255551 Vetter Oct 1993 A
5255669 Kubota et al. Oct 1993 A
5261805 Gates Nov 1993 A
5261877 Fine et al. Nov 1993 A
5263928 Trauthen et al. Nov 1993 A
5263932 Jang Nov 1993 A
5267954 Nita Dec 1993 A
5267958 Buchbinder et al. Dec 1993 A
5267982 Sylvanowicz Dec 1993 A
5269297 Weng et al. Dec 1993 A
5271735 Greenfield et al. Dec 1993 A
5274297 Hermann et al. Dec 1993 A
5285795 Ryan et al. Feb 1994 A
5287775 Moore Feb 1994 A
5290229 Paskar Mar 1994 A
5300021 Wuchinich Apr 1994 A
5300032 Hibbs et al. Apr 1994 A
5300085 Yock Apr 1994 A
5304115 Pflueger et al. Apr 1994 A
5304131 Paskar Apr 1994 A
5304199 Myers Apr 1994 A
5306261 Alliger et al. Apr 1994 A
5307816 Hashimoto et al. May 1994 A
5311858 Adair May 1994 A
5312328 Nita et al. May 1994 A
5312329 Beaty et al. May 1994 A
5312427 Shturman May 1994 A
5315996 Lundquist May 1994 A
5318528 Heaven et al. Jun 1994 A
5319278 Myohga et al. Jun 1994 A
5323902 Palmer et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5324299 Davison et al. Jun 1994 A
5325698 Nagpal et al. Jul 1994 A
5326342 Pflueger et al. Jul 1994 A
5329927 Gardineer et al. Jul 1994 A
5330444 Webler et al. Jul 1994 A
5330482 Gibbs et al. Jul 1994 A
5330497 Freitas et al. Jul 1994 A
5331242 Petri Jul 1994 A
5334160 Ellis Aug 1994 A
5334167 Cocanower Aug 1994 A
5334183 Wuchinich Aug 1994 A
5336184 Teirstein Aug 1994 A
5336234 Vigil et al. Aug 1994 A
5336699 Cooke et al. Aug 1994 A
5342292 Nita et al. Aug 1994 A
5344395 Whalen et al. Sep 1994 A
5350395 Yock Sep 1994 A
5351679 Mayzels et al. Oct 1994 A
5353798 Sieben Oct 1994 A
5356385 Latini Oct 1994 A
5356421 Castro Oct 1994 A
5358505 Wuchinich Oct 1994 A
5362309 Carter Nov 1994 A
5366490 Edwards et al. Nov 1994 A
5366899 Shabalin et al. Nov 1994 A
5368557 Nita et al. Nov 1994 A
5368558 Nita Nov 1994 A
5370602 Kepley Dec 1994 A
5380273 Dubrul et al. Jan 1995 A
5380274 Nita Jan 1995 A
5382228 Nita et al. Jan 1995 A
5385372 Utterberg Jan 1995 A
5387190 Gotanda et al. Feb 1995 A
5387197 Smith et al. Feb 1995 A
5388569 Kepley Feb 1995 A
5390678 Gesswein et al. Feb 1995 A
5391144 Sakurai et al. Feb 1995 A
5396902 Brennen et al. Mar 1995 A
5397293 Alliger et al. Mar 1995 A
5397301 Pflueger et al. Mar 1995 A
5402799 Colon et al. Apr 1995 A
5403324 Ciervo et al. Apr 1995 A
5405318 Nita Apr 1995 A
5405341 Martin Apr 1995 A
5406503 Williams, Jr. et al. Apr 1995 A
5409112 Sagstetter Apr 1995 A
5417654 Kelman May 1995 A
5417672 Nita et al. May 1995 A
5419761 Narayanan et al. May 1995 A
5421338 Crowley et al. Jun 1995 A
5421829 Olichney et al. Jun 1995 A
5423797 Adrian et al. Jun 1995 A
5423838 Willard Jun 1995 A
5425704 Sakurai et al. Jun 1995 A
5427118 Nita et al. Jun 1995 A
5429136 Milo et al. Jul 1995 A
5431664 Ureche et al. Jul 1995 A
5434827 Bolorforosh Jul 1995 A
5443443 Shiber Aug 1995 A
5443456 Alliger et al. Aug 1995 A
5443457 Ginn et al. Aug 1995 A
5443468 Johnson Aug 1995 A
5445617 Yoon Aug 1995 A
5447509 Mills et al. Sep 1995 A
5449369 Imran Sep 1995 A
5451233 Yock Sep 1995 A
5452611 Jones et al. Sep 1995 A
5454373 Koger et al. Oct 1995 A
5458584 Ginn et al. Oct 1995 A
5458612 Chin Oct 1995 A
5460595 Hall et al. Oct 1995 A
5462530 Jang Oct 1995 A
5464016 Nicholas et al. Nov 1995 A
5464409 Mohajer Nov 1995 A
5464438 Menaker Nov 1995 A
5467674 Thorn Nov 1995 A
5469853 Law et al. Nov 1995 A
5470322 Horzewski et al. Nov 1995 A
5472441 Edwards et al. Dec 1995 A
5474075 Goldberg et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5474531 Carter Dec 1995 A
5478353 Yoon Dec 1995 A
5478558 Eibl et al. Dec 1995 A
5484398 Stoddard Jan 1996 A
5492001 Sasaki et al. Feb 1996 A
5498236 Dubrul et al. Mar 1996 A
5501227 Yock Mar 1996 A
5505714 Dassa et al. Apr 1996 A
5507738 Ciervo Apr 1996 A
5512037 Russell et al. Apr 1996 A
5516043 Manna et al. May 1996 A
5524620 Rosenschein Jun 1996 A
5524635 Uflacker et al. Jun 1996 A
5527273 Manna et al. Jun 1996 A
5527279 Imran Jun 1996 A
5531664 Adachi et al. Jul 1996 A
5536250 Klein et al. Jul 1996 A
5540656 Pflueger et al. Jul 1996 A
5542917 Nita et al. Aug 1996 A
5549563 Kronner Aug 1996 A
5549576 Patterson et al. Aug 1996 A
5562620 Klein et al. Oct 1996 A
5569276 Jang et al. Oct 1996 A
5571014 Gregory, Jr. et al. Nov 1996 A
5571085 Accisano, III Nov 1996 A
5575772 Lennox Nov 1996 A
5580962 Eibl et al. Dec 1996 A
5582588 Sakurai et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5590653 Aida et al. Jan 1997 A
5593394 Kanesaka et al. Jan 1997 A
5599326 Carter Feb 1997 A
5603445 Hill et al. Feb 1997 A
5607404 Khairkhahan Mar 1997 A
5607440 Danks et al. Mar 1997 A
5611807 O'Boyle Mar 1997 A
5622170 Schulz Apr 1997 A
5628743 Cimino May 1997 A
5630427 Hastings May 1997 A
5630797 Diedrich et al. May 1997 A
5630837 Crowley May 1997 A
5647846 Berg et al. Jul 1997 A
5651364 Yock Jul 1997 A
5651776 Appling et al. Jul 1997 A
5662620 Lieber et al. Sep 1997 A
5666970 Smith Sep 1997 A
5669881 Dunshee Sep 1997 A
5672172 Zupkas Sep 1997 A
5676011 Allison Oct 1997 A
5676649 Boukhny et al. Oct 1997 A
5681296 Ishida Oct 1997 A
5685312 Yock Nov 1997 A
5687474 Hamzehdoost et al. Nov 1997 A
5688235 Sakurai et al. Nov 1997 A
5690611 Swartz et al. Nov 1997 A
5693029 Leonhardt Dec 1997 A
5704787 Hickok et al. Jan 1998 A
5707359 Bufalini Jan 1998 A
5709120 Shilling Jan 1998 A
5713363 Seward et al. Feb 1998 A
5713848 Dubrul et al. Feb 1998 A
5715825 Crowley Feb 1998 A
5720300 Fagan et al. Feb 1998 A
5720710 Tachibana et al. Feb 1998 A
5722627 Hoshino Mar 1998 A
5725494 Brisken Mar 1998 A
5728062 Brisken Mar 1998 A
5735811 Brisken Apr 1998 A
5741225 Lax et al. Apr 1998 A
5749889 Bacich et al. May 1998 A
5749914 Janssen May 1998 A
5752932 Ellis et al. May 1998 A
5758420 Schmidt et al. Jun 1998 A
5765418 Rosenberg Jun 1998 A
5769868 Yock Jun 1998 A
5772627 Acosta et al. Jun 1998 A
5775328 Lowe et al. Jul 1998 A
5776065 Mehmanpazir et al. Jul 1998 A
5782861 Cragg et al. Jul 1998 A
5797920 Kim Aug 1998 A
5803083 Buck et al. Sep 1998 A
5810860 Adrian Sep 1998 A
5813998 Dias Sep 1998 A
5824042 Lombardi et al. Oct 1998 A
5827203 Nita Oct 1998 A
5827229 Auth et al. Oct 1998 A
5830125 Scribner et al. Nov 1998 A
5830127 DeCastro Nov 1998 A
5830195 Peters et al. Nov 1998 A
5833644 Zadno-Azizi et al. Nov 1998 A
5833650 Imran Nov 1998 A
5836306 Duane et al. Nov 1998 A
5836896 Rosenschein Nov 1998 A
5836897 Sakuri et al. Nov 1998 A
5840027 Swartz et al. Nov 1998 A
5840031 Crowley Nov 1998 A
5840151 Munsch Nov 1998 A
5843017 Yoon Dec 1998 A
5846218 Brisken et al. Dec 1998 A
5849009 Bernaz Dec 1998 A
5861023 Vachon Jan 1999 A
5868773 Danks et al. Feb 1999 A
5868778 Gershony et al. Feb 1999 A
5875782 Ferrari et al. Mar 1999 A
5882347 Mouris-Laan et al. Mar 1999 A
5890406 Thorn Apr 1999 A
5891149 Young et al. Apr 1999 A
5895370 Edwards et al. Apr 1999 A
5895997 Puskas et al. Apr 1999 A
5897557 Chin et al. Apr 1999 A
5897569 Kellogg et al. Apr 1999 A
5902289 Swartz et al. May 1999 A
5904670 Schreiner May 1999 A
5906628 Miyawaki et al. May 1999 A
5908381 Aznoian et al. Jun 1999 A
5910129 Koblish et al. Jun 1999 A
5916192 Nita et al. Jun 1999 A
5916210 Winston Jun 1999 A
5919163 Glickman Jul 1999 A
5919174 Hanson Jul 1999 A
5920395 Schulz Jul 1999 A
5921915 Aznoian et al. Jul 1999 A
5925016 Chornenky et al. Jul 1999 A
5928218 Gelbfish Jul 1999 A
5931805 Brisken Aug 1999 A
5935096 Barrett Aug 1999 A
5935142 Hood Aug 1999 A
5935143 Hood Aug 1999 A
5944687 Benett et al. Aug 1999 A
5951480 White et al. Sep 1999 A
5951539 Nita et al. Sep 1999 A
5951583 Jensen et al. Sep 1999 A
5957882 Nita et al. Sep 1999 A
5961444 Thompson Oct 1999 A
5964756 McGaffigan et al. Oct 1999 A
5971949 Levin et al. Oct 1999 A
5971960 Flom et al. Oct 1999 A
5971983 Lesh Oct 1999 A
5974884 Sano et al. Nov 1999 A
5976093 Jang Nov 1999 A
5980563 Tu et al. Nov 1999 A
5981444 Sawada et al. Nov 1999 A
5984882 Rosenschein et al. Nov 1999 A
5984950 Cragg et al. Nov 1999 A
5987349 Schulz Nov 1999 A
5989208 Nita Nov 1999 A
5989209 Barrett Nov 1999 A
5989274 Davison et al. Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
5993408 Zaleski Nov 1999 A
5997497 Nita et al. Dec 1999 A
5997523 Jang Dec 1999 A
6001355 Dowdle Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6007514 Nita Dec 1999 A
6010476 Saadat Jan 2000 A
6010498 Guglielmi Jan 2000 A
6017340 Cassidy et al. Jan 2000 A
6017354 Culp et al. Jan 2000 A
6017359 Gershony et al. Jan 2000 A
6019777 Mackenzie Feb 2000 A
6021694 Beger Feb 2000 A
6022336 Zadno-Azizi et al. Feb 2000 A
6022369 Jacobsen et al. Feb 2000 A
6024718 Chen et al. Feb 2000 A
6027515 Cimino Feb 2000 A
6032078 Rudie Feb 2000 A
6033375 Brumbach Mar 2000 A
6033411 Preissman Mar 2000 A
6036648 White et al. Mar 2000 A
6036671 Frey Mar 2000 A
6036697 DiCaprio Mar 2000 A
6036715 Yock Mar 2000 A
6039693 Seward et al. Mar 2000 A
6039762 McKay Mar 2000 A
6045527 Appelbaum et al. Apr 2000 A
6048329 Thompson et al. Apr 2000 A
6050949 White et al. Apr 2000 A
6051772 Cameron et al. Apr 2000 A
6053904 Scribner et al. Apr 2000 A
RE36693 Reich May 2000 E
6056722 Jayaraman May 2000 A
6057798 Burrier et al. May 2000 A
6059789 Dinger et al. May 2000 A
6062001 Kunik May 2000 A
6062059 Feldcamp May 2000 A
6068610 Ellis et al. May 2000 A
6077285 Boukhny Jun 2000 A
6083191 Rose Jul 2000 A
6083501 Miyata et al. Jul 2000 A
6090118 McGuckin, Jr. Jul 2000 A
6099464 Shimizu et al. Aug 2000 A
6106475 Lowe et al. Aug 2000 A
6106538 Shiber Aug 2000 A
6107161 Kitaguro et al. Aug 2000 A
6110142 Pinchuk et al. Aug 2000 A
6110176 Shapira Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6113570 Siegel et al. Sep 2000 A
6113580 Dolisi Sep 2000 A
6123718 Tu et al. Sep 2000 A
6124150 Corisis Sep 2000 A
6124546 Hayward et al. Sep 2000 A
6124634 Akram et al. Sep 2000 A
6129672 Seward et al. Oct 2000 A
6146380 Racz et al. Nov 2000 A
6146381 Bowe et al. Nov 2000 A
6156018 Hassett Dec 2000 A
6159195 Ha et al. Dec 2000 A
6162053 Hollander Dec 2000 A
6165197 Yock Dec 2000 A
6190353 Makower et al. Feb 2001 B1
6193683 Ludin et al. Feb 2001 B1
6200269 Lin et al. Mar 2001 B1
6200315 Gaiser et al. Mar 2001 B1
6203516 Kepley Mar 2001 B1
6203568 Lombardi et al. Mar 2001 B1
6224565 Cimino May 2001 B1
6228046 Brisken May 2001 B1
6231514 Lowe et al. May 2001 B1
6231518 Grabek et al. May 2001 B1
6234971 Jang May 2001 B1
6235000 Milo et al. May 2001 B1
6241703 Levin et al. Jun 2001 B1
6245095 Dobak, III et al. Jun 2001 B1
6247592 Racicot et al. Jun 2001 B1
6258798 Wallentin Jul 2001 B1
6262062 Clemens Jul 2001 B1
6270460 McCartan et al. Aug 2001 B1
6277084 Abele et al. Aug 2001 B1
6279743 Ballard et al. Aug 2001 B1
6280413 Clark et al. Aug 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6287271 Dubrul et al. Sep 2001 B1
6287272 Brisken et al. Sep 2001 B1
6290662 Morris et al. Sep 2001 B1
6290673 Shanley Sep 2001 B1
6293725 Winkvist Sep 2001 B1
6296658 Gershony et al. Oct 2001 B1
6303635 Kawai et al. Oct 2001 B1
6306097 Park et al. Oct 2001 B1
6307156 Avellanet Oct 2001 B1
6309379 Willard et al. Oct 2001 B1
6312406 Jayaraman Nov 2001 B1
6322541 West et al. Nov 2001 B2
6329778 Culp et al. Dec 2001 B1
6346091 Jacobsen et al. Feb 2002 B1
6348039 Flachman et al. Feb 2002 B1
6358252 Shapira Mar 2002 B1
6364840 Crowley Apr 2002 B1
6364841 White et al. Apr 2002 B1
6368611 Whitbourne et al. Apr 2002 B1
6376513 Akahane et al. Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6391042 Cimino May 2002 B1
6396293 Vinther et al. May 2002 B1
6398776 Sekino et al. Jun 2002 B1
6398792 O'Connor Jun 2002 B1
6410560 Akahane et al. Jun 2002 B1
6416511 Lesh et al. Jul 2002 B1
6416530 DeVries et al. Jul 2002 B2
6416737 Manolagas et al. Jul 2002 B1
6419644 White et al. Jul 2002 B1
6433464 Jones Aug 2002 B2
6440726 Resnick Aug 2002 B1
6440947 Barron et al. Aug 2002 B1
6443903 White et al. Sep 2002 B1
6450975 Brennan et al. Sep 2002 B1
6451303 Whitehouse et al. Sep 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6457365 Stephens et al. Oct 2002 B1
6458375 Gertzman et al. Oct 2002 B1
6462172 Maclennan et al. Oct 2002 B1
6464660 Brisken et al. Oct 2002 B2
6469419 Kato et al. Oct 2002 B2
6471656 Shalman et al. Oct 2002 B1
6475185 Rauker et al. Nov 2002 B1
6478751 Krueger et al. Nov 2002 B1
6482218 Tran Nov 2002 B1
6485481 Pfeiffer Nov 2002 B1
6491710 Satake Dec 2002 B2
6491711 Durcan Dec 2002 B1
6494883 Ferree Dec 2002 B1
6494885 Dhindsa Dec 2002 B1
6494891 Cornish et al. Dec 2002 B1
6494893 Dubrul et al. Dec 2002 B2
6497667 Miller et al. Dec 2002 B1
6497698 Fonger et al. Dec 2002 B1
6503223 Sekido et al. Jan 2003 B1
6508781 Brennan et al. Jan 2003 B1
6508782 Evans et al. Jan 2003 B1
6509348 Ogletree Jan 2003 B1
6511492 Rosenbluth et al. Jan 2003 B1
6512957 Witte Jan 2003 B1
6514210 Ohara et al. Feb 2003 B2
6522929 Swing Feb 2003 B2
6524251 Rabiner et al. Feb 2003 B2
6527115 Rabiner et al. Mar 2003 B2
6530923 Dubrul et al. Mar 2003 B1
6544276 Azizi Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6544541 Zahradka Apr 2003 B1
6547724 Soble et al. Apr 2003 B1
6547754 Evans et al. Apr 2003 B1
6551269 Clemens et al. Apr 2003 B2
6551327 Dhindsa Apr 2003 B1
6551337 Rabiner et al. Apr 2003 B1
6558334 Shalman et al. May 2003 B2
6569109 Sakurai et al. May 2003 B2
6569148 Bagaoisan et al. May 2003 B2
6572555 White et al. Jun 2003 B2
6575959 Sarge et al. Jun 2003 B1
6575993 Yock Jun 2003 B1
6577042 Lee et al. Jun 2003 B2
6579277 Rabiner et al. Jun 2003 B1
6579279 Rabiner et al. Jun 2003 B1
6579302 Duerig et al. Jun 2003 B2
6585657 Yock Jul 2003 B2
6589253 Cornish et al. Jul 2003 B1
6592548 Jayaraman Jul 2003 B2
6596020 Vardi et al. Jul 2003 B2
6605074 Zadno-Azizi et al. Aug 2003 B2
6611793 Burnside et al. Aug 2003 B1
6615080 Unsworth et al. Sep 2003 B1
6617760 Peterson et al. Sep 2003 B1
6620113 White et al. Sep 2003 B2
6626853 White et al. Sep 2003 B2
6626926 Friedman et al. Sep 2003 B2
6629948 Rockley et al. Oct 2003 B2
6645149 Smith Nov 2003 B1
6645152 Jung et al. Nov 2003 B1
6647755 Rabiner et al. Nov 2003 B2
6648881 KenKnight et al. Nov 2003 B2
6652547 Rabiner et al. Nov 2003 B2
6655386 Makower et al. Dec 2003 B1
6660013 Rabiner et al. Dec 2003 B2
6669665 Jayaraman Dec 2003 B2
6679873 Rabiner et al. Jan 2004 B2
6682556 Ischinger Jan 2004 B1
6689086 Nita et al. Feb 2004 B1
6689087 Pal et al. Feb 2004 B2
6692460 Jayaraman Feb 2004 B1
6695781 Rabiner et al. Feb 2004 B2
6695782 Ranucci et al. Feb 2004 B2
6702748 Nita et al. Mar 2004 B1
6702750 Yock Mar 2004 B2
6712766 Harada Mar 2004 B2
6726698 Cimino Apr 2004 B2
D489973 Root et al. May 2004 S
6730037 Jang May 2004 B2
6730048 Hare et al. May 2004 B1
6733451 Rabiner et al. May 2004 B2
6760165 Wulff et al. Jul 2004 B2
6761690 Sakurai et al. Jul 2004 B2
6790204 Zadno-Azizi et al. Sep 2004 B2
6802835 Rabiner et al. Oct 2004 B2
6840952 Saker et al. Jan 2005 B2
6849062 Kantor Feb 2005 B2
6855123 Nita Feb 2005 B2
6855125 Shanley Feb 2005 B2
6860876 Chen Mar 2005 B2
6866670 Rabiner et al. Mar 2005 B2
6878106 Herrmann Apr 2005 B1
6887257 Salahieh et al. May 2005 B2
6908472 Wiener et al. Jun 2005 B2
6921411 Yock Jul 2005 B2
6923788 Kantor Aug 2005 B2
6929632 Nita et al. Aug 2005 B2
6939317 Zacharias Sep 2005 B2
6942620 Nita et al. Sep 2005 B2
6942677 Nita et al. Sep 2005 B2
6966891 Ookubo et al. Nov 2005 B2
6984220 Wuchinich Jan 2006 B2
20010047166 Wuchinich Nov 2001 A1
20020007130 Burbank et al. Jan 2002 A1
20020016565 Zadno-Azizi et al. Feb 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020029054 Rabiner et al. Mar 2002 A1
20020055754 Ranucci et al. May 2002 A1
20020077550 Rabiner et al. Jun 2002 A1
20020077643 Rabiner et al. Jun 2002 A1
20020082503 Chandrasekaran et al. Jun 2002 A1
20020091407 Zadno-Azizi et al. Jul 2002 A1
20020095141 Belef et al. Jul 2002 A1
20020107446 Rabiner et al. Aug 2002 A1
20030009125 Nita et al. Jan 2003 A1
20030045835 Anderson et al. Mar 2003 A1
20030045887 Sakurai et al. Mar 2003 A1
20030048037 Boyd Mar 2003 A1
20030074006 Mowry et al. Apr 2003 A1
20030114732 Webler et al. Jun 2003 A1
20030120208 Houser et al. Jun 2003 A1
20030125751 Griffin et al. Jul 2003 A1
20030176791 Rabiner et al. Sep 2003 A1
20030181923 Vardi Sep 2003 A1
20030197958 Wulff et al. Oct 2003 A1
20030212331 Fenton et al. Nov 2003 A1
20030225332 Okada et al. Dec 2003 A1
20030236539 Rabiner et al. Dec 2003 A1
20040019266 Marciante et al. Jan 2004 A1
20040024393 Nita et al. Feb 2004 A1
20040024402 Nita Feb 2004 A1
20040039311 Nita et al. Feb 2004 A1
20040039375 Miyazawa Feb 2004 A1
20040059227 Nita et al. Mar 2004 A1
20040059280 Makower et al. Mar 2004 A1
20040068189 Wilson et al. Apr 2004 A1
20040097996 Rabiner et al. May 2004 A1
20040106866 Ookubo et al. Jun 2004 A1
20040119287 Williams et al. Jun 2004 A1
20040138570 Nita et al. Jul 2004 A1
20040167507 Nita et al. Aug 2004 A1
20040199228 Wilson Oct 2004 A1
20040204670 Nita et al. Oct 2004 A1
20040204729 Cimino Oct 2004 A1
20040210140 Rabiner et al. Oct 2004 A1
20040213866 Wulff et al. Oct 2004 A1
20040243052 Kauphusman et al. Dec 2004 A1
20050043629 Rabiner et al. Feb 2005 A1
20050059991 Shanley Mar 2005 A1
20050070794 Deal et al. Mar 2005 A1
20050101870 Yamaguchi et al. May 2005 A1
20050101906 Nita May 2005 A1
20050113688 Nita et al. May 2005 A1
20050119606 Nita Jun 2005 A1
20050124877 Nita et al. Jun 2005 A1
20050171570 Yock Aug 2005 A1
20050209677 Shaked Sep 2005 A1
20050240165 Miki et al. Oct 2005 A1
20050245951 Nita et al. Nov 2005 A1
20050277577 Hunter et al. Dec 2005 A1
20050283080 Nita et al. Dec 2005 A1
Foreign Referenced Citations (44)
Number Date Country
2251096 Aug 1998 CA
2320300 Aug 1999 CA
2 362 689 Sep 2000 CA
428980 May 1926 DE
203 229 Oct 1983 DE
37 31 482 Apr 1988 DE
0 121 491 Oct 1984 EP
0 243 298 Oct 1987 EP
0 293 472 Dec 1988 EP
0293472 Dec 1988 EP
0 316 796 May 1989 EP
0 353 294 Feb 1990 EP
0 493 047 Jul 1992 EP
0 541 249 May 1993 EP
0 542 103 May 1993 EP
0541249 May 1993 EP
0 891 744 Jan 1999 EP
461395 Dec 1913 FR
2 614 524 Nov 1988 FR
19559 Sep 1899 GB
1 371 335 Oct 1974 GB
2 032 221 Apr 1980 GB
2 325 192 Nov 1998 GB
62-224339 Mar 1986 JP
64-027548 Jan 1989 JP
02092348 Apr 1990 JP
WO 8701276 Mar 1987 WO
WO 8906515 Jul 1989 WO
WO 9001300 Feb 1990 WO
WO 9010423 Sep 1990 WO
WO 9107138 May 1991 WO
WO 9204071 Mar 1992 WO
WO 9211815 Jul 1992 WO
WO 9316646 Sep 1993 WO
WO 9503740 Feb 1995 WO
WO 9607377 Mar 1996 WO
WO 9835721 Aug 1998 WO
WO 9855032 Dec 1998 WO
WO 9916360 Apr 1999 WO
WO 9933404 Jul 1999 WO
WO 9935982 Jul 1999 WO
WO 9939647 Aug 1999 WO
WO 0021444 Apr 2000 WO
WO 0053263 Sep 2000 WO
Related Publications (1)
Number Date Country
20030176791 A1 Sep 2003 US
Provisional Applications (2)
Number Date Country
60178901 Jan 2000 US
60157824 Oct 1999 US
Continuations (1)
Number Date Country
Parent 09784619 Feb 2001 US
Child 10373134 US
Continuation in Parts (1)
Number Date Country
Parent 09618352 Jul 2000 US
Child 09784619 US